Delcath Systems, Inc.

NASDAQ:DCTH

Medical - Devices

Healthcare
$19.70 -1.91%

-$0.23 today

Market cap
$685.32M
Beta
0.52
P/E (TTM)
751.4
EPS (TTM)
$0.02
52W Low $8.12High $14.48

Volume 0.59M

Average 0.42M

DCTH Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Delcath Systems, Inc.NASDAQ: DCTH

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation dips below year-ago levels

Q1 FY2026 stock-based compensation of $4.95M fell 27.9% year over year, behind the +63.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 9.6% from the prior quarter. Over 3 fiscal years it compounded at +45.0% a year.

Context

  • Stock-based compensation amounted to 28.4% of revenue in FY2025, up 2.2 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -27.9% toward the trailing-twelve-month pace of +63.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.95M+9.6% QoQ
Last fiscal yearDec 2025
$24.23M+148.1% YoY
LTMMar 2026
$22.32M+63.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-27.9%——
1 year+148.1%——
3-year CAGR+45.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
24.23M USD
Year-over-year change
+148.1%
4-year CAGR
+32.6%

Stock-Based Compensation vs competitors

How DCTH compares with its peers on the latest reported figures

  • DCTH's LTM Mar 2026 stock-based compensation of $22.32M is the 2nd largest of the 4 companies compared; the peer median is $9.98M.
  • Its year-over-year change of +63.1% is the 2nd highest of 4, against a peer median of +38.0%.
  • Stock-based compensation amounts to 24.7% of revenue for DCTH, versus a peer median of 22.2%.
DCTH Competitors Peer median
Stock-Based Compensation for DCTH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVCRNovoCure LimitedLTM Mar 2026$118.47M -23.8%—17.6%
DCTHDelcath Systems, Inc.LTM Mar 2026$22.32M +63.1%+45.0%24.7%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$9.98M +67.1%+191.7%22.2%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$9.42M +38.0%+88.2%1524.4%
Peer median (excluding DCTH) $9.98M+38.0%+140.0%22.2%

Competitors are the stored peer set for DCTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(25.65M)(36.51M)(47.68M)(26.39M)2.7M
Depreciation & Amortization146K132K128K229K349K
Deferred Income Tax00000
Stock-Based Compensation7.83M7.94M8.15M9.77M24.23M
Change in Working Capital(5.76M)2.11M(906K)(15.52M)(3.07M)
Accounts Receivables13K(322K)125K(10.65M)(854K)
Inventory(557K)(587K)(1.32M)(3.61M)(3.32M)
Accounts Payables(1.14M)1.8M(199K)479K4.77M
Other Working Capital(4.08M)1.23M492K(1.74M)(3.66M)
Other Non-Cash Items831K1.37M9.05M13.23M(1.7M)
Operating Cash Flow(22.6M)(24.95M)(31.25M)(18.68M)22.52M
Capital Expenditures(143K)(209K)(58K)(559K)(1.55M)
Acquisitions (Net)00000
Purchases of Investments00(19.65M)(52.45M)(93.22M)
Sales of Investments00052.03M68.17M
Other Investing Activities00000
Investing Cash Flow(143K)(209K)(19.71M)(981K)(26.59M)
Debt Repayment14.44M(714K)(6.31M)(10.61M)0
Common Stock Issued3.92M10.86M23.08M7.02M21.05M
Common Stock Repurchased0000(6M)
Dividends Paid00000
Other Financing Activities2.46M035.01M43M0
Financing Cash Flow20.82M10.14M51.78M39.41M15.05M
Effect of Forex Changes122K(115K)56K(32K)68K
Net Change in Cash(1.8M)(15.13M)874K19.72M11.04M
Free Cash Flow(22.75M)(25.16M)(31.31M)(19.24M)20.97M

Delcath Systems, Inc.

NASDAQ:DCTH

Intrinsic Alpha fair value

Locked

Current Price

$19.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.